T-cell engaging antibodies: what lessons have we learnt?
The use of T-cell engaging antibodies for acute myeloid leukemia (AML) treatment is in the very early stages. In this interview, Marion Subklewe, MD, of the University of Munich, Munich, Germany, high...
Author: VJHemOnc
Added: 11/28/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Germany Health | Learning | Lessons | Leukemia